Skipping Breakfast and Cardiovascular Risk

Several studies have associated skipping breakfast (having little to no breakfast) with increased cardiometabolic risk factors such as obesity, hypertension, dyslipidemia, diabetes and metabolic syndrome. 

Saltearse el desayuno y riesgo cardiovascular

This study examined all the available evidence on the association of skipping breakfast and cardiovascular and all-cause mortality.

It included 4 studies with close to 200,000 adults (mean age ≥40, 48.5% women) with no known cardiovascular disease at recruiting, followed up for mean 17.4 years.

The general analysis suggests that the population which regularly skips breakfast has 21% higher risk of CAD or cardiac death (HR 1.21, CI 95% 1.08 to 1.35; p=0.304) than those that regularly have breakfast.


Read also: Egg Consumption and Mortality Due to Cardiovascular Events.


Even all cause death risk was 32% higher in patients that skip breakfast (HR 1.32, CI 95% 1.17 to 1.48; p=0.339).

Looking closer, we find that the definition of “no breakfast” was heterogeneous between the studies and that the populations were also different, which might have led to misleading outcomes, regardless adjustments. 

Robust data call for further study at long term with consistent definitions of “no breakfast”. 


Read also: Artificially Sweetened Beverages and Alzheimer Risk.


Meanwhile, it seems reasonable (within the primary prevention scope) to recommend our patients have breakfast, which should the most important meal. 

2020-01-16-jcdd-06-00030

Original Title: Skipping Breakfast and the Risk of Cardiovascular Disease and Death: A Systematic Review of Prospective Cohort Studies in Primary Prevention Settings.

Reference: Richard Ofori-Asenso et al. J Cardiovasc Dev Dis 6 (3) 2019 Aug 22.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

AHA 2024 | VANISH2 Trial

Cardiac defibrillator implants (CDIs) have been shown to improve survival in patients with ischemic cardiomyopathy and ventricular tachycardia (VT). However, approximately one third of...

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...

STEACS and the Use of Bivalirudin vs. Heparin: In Search of BRIGHT-4 Outcomes

Various studies and registries have previously shown the impact of post-percutaneous coronary intervention (PCI) complications on the survival of patients with ST-segment elevation acute...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Sievers Type 1 Bicuspid Valves: Which to Use?

One of the current challenges in TAVR is bicuspid aortic valves (BAV), because of their anatomical complexity, calcification, raphe presence, aortic dilation and associated...

AHA 2024 | VANISH2 Trial

Cardiac defibrillator implants (CDIs) have been shown to improve survival in patients with ischemic cardiomyopathy and ventricular tachycardia (VT). However, approximately one third of...

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...